Privately-held German drugmaker Boehringer Ingelheim has announced its financial results for the first half of 2023.
Currency-adjusted net sales rose by 9.7% to 12.2 billion euros ($13.5 billion), with the figure specifically for the Human Pharma division standing at 9.6 billion euros, an 11.3% jump.
Boehringer attributes the growth partly to Jardiance’s (empagliflozin) 3.5 billion euros in sales and the 1.7 billion euros from the respiratory medicine Ofev (nintedanib).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze